Drug Profile
Research programme: histamine H1 receptor modulators - Eli Lilly and Company
Alternative Names: HY-10427Latest Information Update: 21 Apr 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Dibenzoxazepines; Small molecules
- Mechanism of Action Histamine H1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Insomnia
Most Recent Events
- 21 Apr 2009 No development reported - Preclinical for Insomnia in USA (unspecified route)
- 03 Apr 2007 Hypnion has been acquired and merged into Eli Lilly and Company
- 19 Dec 2005 Preclinical trials in Insomnia in USA (unspecified route)